



A comprehensive review of pediatric obesity: Causes, consequences, and multicomponent treatment approaches

Kompleksowy przegląd otyłości pediatrycznej: przyczyny, konsekwencje oraz wieloskładnikowe podejścia terapeutyczne

Aleksandra Zagórska¹ , Michał Kotowicz¹ , Magdalena Zielińska¹ , Paweł Szajewski¹ , Joanna Cieciewicz¹ ,
Maria Koczkodaj² , Magdalena Bieniak³ 

¹Szpital Wolski im. dr Anny Gostyńskiej Sp. z o.o., Warszawa, Polska /
Dr. Anna Gostyńska Wolski Hospital, Warsaw, Poland

²Warszawski Szpital Południowy Sp. z o.o., Polska / Warsaw Southern Hospital, Warsaw, Poland

³Szpital Praski p.w. Przemienienia Pańskiego Sp. z o.o., Warszawa, Polska /
Praski Hospital of the Transfiguration of Our Lord, Warsaw, Poland

ABSTRACT

Pediatric obesity has emerged as one of the most pressing public health challenges of the 21st century, with significant implications for both physical and psychological well-being. This review synthesizes current evidence on the multifactorial causes, health consequences, and management strategies for childhood and adolescent obesity. The development of obesity early in life is shaped by complex interactions among genetic, epigenetic, environmental, behavioral, and socioeconomic factors. Key contributors include poor dietary habits, sedentary lifestyle, maternal and prenatal influences, and psychosocial determinants. The consequences of pediatric obesity extend far beyond excess adiposity, encompassing cardiometabolic disorders, orthopedic problems, respiratory dysfunction, and psychosocial impairments. Effective management requires an individualized, multidisciplinary, and family-centered approach. Evidence supports multicomponent interventions that integrate dietary modification, increased physical activity, behavioral and psychological support, and – in selected cases – pharmacological or surgical treatment. Pharmacotherapy with glucagon-like peptide-1 receptor agonists, such as liraglutide and semaglutide, has shown promising results in adolescents with severe obesity, while bariatric surgery remains a viable option for refractory cases. Emerging personalized, pathophysiology-informed strategies and novel pharmacologic agents offer new opportunities for targeted intervention. Addressing pediatric obesity necessitates long-term, comprehensive, and sustainable efforts that engage healthcare systems, families, and communities to mitigate the escalating burden of this condition.

KEYWORDS

pediatric obesity, adolescent obesity, lifestyle interventions, bariatric surgery, prevention, multicomponent treatment

Received: 30.10.2025

Revised: 25.11.2025

Accepted: 25.11.2025

Published online: 19.06.2026

Address for correspondence: lek. Aleksandra Zagórska, Szpital Wolski im. dr Anny Gostyńskiej, ul. Marcina Kasprzaka 17, 01-211 Warszawa, tel. +48 518 347 877, e-mail: aleksandra.zagorska00@gmail.com



This is an open access article made available under the terms of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license, which defines the rules for its use. It is allowed to copy, alter, distribute and present the work for any purpose, even commercially, provided that appropriate credit is given to the author and that the user indicates whether the publication has been modified, and when processing or creating based on the work, you must share your work under the same license as the original. The full terms of this license are available at <https://creativecommons.org/licenses/by-sa/4.0/legalcode>.

© Copyright by Author(s)

Publisher: Medical University of Silesia, Katowice, Poland



STRESZCZENIE

Otyłość wieku rozwojowego stała się jednym z najpoważniejszych wyzwań zdrowia publicznego XXI wieku, niosąc istotne konsekwencje zarówno dla zdrowia fizycznego, jak i psychicznego. W niniejszej pracy przeglądowej przedstawiono aktualny stan wiedzy dotyczący wieloczynnikowej etiologii, następstw zdrowotnych oraz strategii leczenia otyłości u dzieci i młodzieży. Rozwój otyłości we wczesnym okresie życia jest wynikiem złożonych interakcji pomiędzy czynnikami genetycznymi, epigenetycznymi, środowiskowymi, behawioralnymi i społeczno-ekonomicznymi. Do głównych czynników sprzyjających temu schorzeniu należą nieprawidłowe nawyki żywieniowe, niewystarczająca aktywność fizyczna, czynniki matczyne i prenatalne oraz uwarunkowania psychospołeczne. Konsekwencje otyłości wieku rozwojowego wykraczają poza nadmierne nagromadzenie tkanki tłuszczowej i obejmują zaburzenia kardiometaboliczne, schorzenia układu kostno-stawowego, zaburzenia oddychania oraz problemy psychospołeczne. Skuteczne postępowanie wymaga zindywidualizowanego, wielodyscyplinarnego i skoncentrowanego na rodzinie podejścia. Dostępne dane naukowe potwierdzają skuteczność wielokomponentowych interwencji, obejmujących modyfikację sposobu żywienia, zwiększenie aktywności fizycznej oraz wsparcie behawioralne i psychologiczne, a w wybranych przypadkach również leczenie farmakologiczne lub chirurgiczne. Farmakoterapia z zastosowaniem agonistów receptora glukagonopodobnego peptydu 1, takich jak liraglutyd i semaglutyd, daje obiecujące wyniki u młodzieży z ciężką otyłością, natomiast chirurgia bariatryczna pozostaje skuteczną metodą leczenia w przypadkach opornych na postępowanie zachowawcze. Rozwijające się strategie spersonalizowanego leczenia opartego na patofizjologii choroby oraz nowe leki przeciwotyłościowe stwarzają nowe możliwości terapii celowanej. Skuteczne przeciwdziałanie otyłości wieku rozwojowego wymaga długofalowych, kompleksowych i trwałych działań angażujących system ochrony zdrowia, rodziny oraz społeczności lokalne w celu ograniczenia narastającego obciążenia związanego z tym schorzeniem.

SŁOWA KLUCZOWE

otyłość wieku rozwojowego, otyłość młodzieży, interwencje dotyczące stylu życia, chirurgia bariatryczna, profilaktyka, leczenie wielokomponentowe

INTRODUCTION

Childhood and adolescent obesity has emerged as one of the most significant public health concerns of the 21st century. The global prevalence of excess body weight among young people continues to rise, affecting nearly one in five children and adolescents worldwide [1]. This increasing trend is observed not only in high-income nations, but also across low- and middle-income countries (LMICs), where rapid urbanization, changes in dietary patterns, and reduced physical activity have contributed to an expanding epidemic. The World Health Organization (WHO) defines overweight and obesity as abnormal or excessive fat accumulation that poses a risk to health, typically assessed through age- and sex-adjusted body mass index (BMI). Central adiposity in particular is closely linked to adverse cardiometabolic profiles and increased morbidity in childhood and later life [2].

The causes of pediatric obesity are multifactorial and extend beyond the simplistic notion of an imbalance between energy intake and expenditure. Rather, obesity represents the outcome of a complex interplay between genetic susceptibility, metabolic regulation, behavioral habits, and socio-environmental conditions throughout one's life. Genetic and epigenetic mechanisms influence individual predisposition, while lifestyle and environmental exposures – such as inadequate physical activity, high consumption of processed foods, poor sleep hygiene, and social disadvantage – amplify the risk. Early-life determinants, including maternal health,

intrauterine environment, and infant feeding practices, further shape long-term metabolic outcomes [3].

The persistence of obesity from childhood into adulthood is a well-established phenomenon, with approximately 80% of obese adolescents remaining obese as adults and about 70% continuing beyond the age of 30 [1]. This continuity significantly increases the risk of cardiovascular, cerebrovascular, and metabolic diseases, as well as psychological and social complications [1,2]. Consequently, the prevention of childhood obesity has become a global public health priority. Evidence indicates that early preventive interventions are more cost-effective and yield better long-term outcomes than treatment in adulthood [1]. Comprehensive prevention strategies should therefore combine public education, family-centered interventions, and supportive environments that promote healthy lifestyles from early childhood [2].

This review provides an evidence-based overview of the current understanding of pediatric obesity, including its prevalence, contributing factors, preventive approaches, and therapeutic interventions.

METHODOLOGY

This narrative review used a structured literature search focusing on childhood and adolescent obesity. A systematic search of the PubMed database was performed for publications released between January 2010 and October 2024. To identify relevant studies, the following keywords and their combinations were



applied: “childhood obesity,” “adolescent obesity,” “pediatric overweight,” “etiology,” “risk factors,” “epidemiology,” “COVID-19,” “prevention,” “management,” “lifestyle interventions,” “pharmacotherapy,” and “bariatric surgery.”

The inclusion criteria were as follows:

- peer-reviewed articles published in English or Polish
- studies addressing epidemiology, etiological determinants, health consequences, preventive strategies, clinical assessment, or treatment of pediatric obesity
- systematic reviews, meta-analyses, clinical practice guidelines, randomized or non-randomized clinical trials, and large observational studies.

The exclusion criteria included:

- publications involving individuals under 18 years of age
- articles lacking accessible full text
- commentaries, editorials, conference abstracts without methodological detail, and studies which are insufficiently related to the scope of this review.

To ensure completeness, the reference lists of key articles and major reviews were screened manually for additional eligible sources. After removing duplicates and applying the eligibility criteria, a final set of publications consistent with the requirements was included in the synthesis presented in this manuscript.

DISCUSSION

Epidemiology of childhood obesity

Childhood and adolescent obesity is a growing global health concern that affects both high-income countries and, increasingly, LMICs [4]. Recent projections by the World Obesity Federation predict that by 2030, this disease may affect 254 million children and adolescents aged 5 to 19 years [5].

Although obesity rates remain highest in nations such as the United States, Canada, and parts of Europe, a steep rise is now being observed in LMICs, particularly in Asia, the Middle East, and Latin America [6,7]. In many of these regions, the coexistence of undernutrition and obesity presents a dual burden of malnutrition [8].

In Europe, the WHO Regional Office for Europe reported that in some countries, up to 30% of children are overweight or obese [8]. The Childhood Obesity Surveillance Initiative, which covers over 40 countries, found wide variation across Europe, with the highest rates being in Mediterranean countries such as Greece, Italy, and Spain [9]. In Poland, national data indicate

a consistent upward trend in the prevalence of excess body weight among children and adolescents. The 2018 Health Behaviour in School-aged Children (HBSC) study reported that approximately 18% of Polish adolescents aged 11–15 years were classified as overweight or obese [10].

Impact of COVID-19 on pediatric obesity

These rising trends set the stage for exploring how acute disruptions such as the coronavirus disease 2019 (COVID-19) pandemic further influenced pediatric obesity patterns. School closures and prolonged home confinement resulted in reduced physical activity and increased screen exposure, while heightened stress and disrupted daily routines contributed to irregular eating patterns [11].

Reports from multiple regions – including China, Europe, and the USA – indicated accelerated weight gain during lockdowns, driven primarily by decreased movement and changes in dietary habits [2]. The term “covibesity” has been introduced to describe this trend. Pediatric obesity has also been associated with more severe COVID-19 outcomes, although most infected children continue to experience mild disease [11].

Understanding the interplay of pandemic-related behaviors and established etiological factors provides insight into the multifactorial nature of obesity development.

Causes of childhood and adolescent obesity

Childhood obesity develops through the combined influence of genetic susceptibility, prenatal and early-life exposures, lifestyle behaviors, and environmental conditions [2,3].

Dietary and lifestyle factors

High consumption of energy-dense foods and low levels of physical activity contribute to a positive energy balance. Sedentary behaviors, including prolonged screen use and reduced overall movement, are linked with disrupted daily routines. In contrast, regular physical activity supports healthy weight regulation and cardiometabolic outcomes [2].

Early-life and maternal influences

Maternal factors such as pre-pregnancy obesity, excessive gestational weight gain, and gestational diabetes increase the risk of obesity in offspring. Prenatal exposures – including stress, smoking, air pollution, and certain nutritional deficiencies – affect fetal metabolic programming. Early postnatal patterns, such as rapid infant weight gain, also contribute to long-term obesity risk [3].



Genetic and epigenetic contributions

Genetic predisposition shapes individual vulnerability to obesity, with numerous genes influencing appetite regulation, metabolism, and fat distribution. Epigenetic modifications resulting from prenatal and early-life exposures may further alter metabolic pathways and contribute to intergenerational transmission of obesity risk [3].

Family and psychosocial environment

Family routines, parental feeding practices, and socioeconomic constraints significantly influence children's eating habits and activity patterns. Household stress and limited access to healthy foods can amplify obesity risk. Neurodevelopmental conditions such as ADHD and ASD are also associated with challenges in maintaining healthy lifestyle habits [3].

Medical and pharmacological contributors

Certain endocrine disorders and central nervous system injuries are recognized contributors to pediatric weight gain. Additionally, medications such as glucocorticoids, antiepileptics, insulin, and atypical antipsychotics may promote adiposity and should be considered during clinical evaluation [2].

Strategies for managing obesity in children and adolescents

Principles of pediatric obesity management

Effective management should be grounded in a comprehensive assessment of both the child and their family, consistent with established guidelines. Multicomponent interventions integrating at least two elements – such as physical activity, nutritional counseling, psychological support, or technology-based tools – represent the foundation of care. Treatment should be individualized and developed through shared decision-making [12]. Nutritional strategies and the promotion of physical activity are key components, complemented by psychological interventions aimed at fostering behavioral change. Currently, the available evidence is insufficient to make recommendations for or against technology-based interventions in the treatment of pediatric obesity [12]. In selected cases, particularly among older children, pharmacologic therapy may be considered as an adjunct. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and biguanides are options for patients aged 12 years and older, while lipase inhibitors are not recommended in the pediatric population. Severe obesity unresponsive to conservative measures may warrant surgical interventions, including laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass, for

adolescents aged 13 years and older; such cases are to be evaluated by a specialized multidisciplinary team [12].

Lifestyle interventions

Dietary approaches

Short-term low-carbohydrate interventions can aid in weight reduction and improve cardiometabolic outcomes, even without strict calorie restriction. However, limited trials and heterogeneity constrain firm conclusions versus traditional calorie-restricted diets [13].

Effective care integrates nutritional modification, increased physical activity, reduced sedentary time, and improved sleep. Adolescents may also benefit from structured dietary programs, pharmacotherapy, or bariatric procedures. Prevention requires coordinated, evidence-based public health strategies [14]. Structured nutrition guidance encourages local dietary patterns, fruits and vegetables, limited energy-dense foods and sugary drinks, and regular family meals. The traffic light diet categorizes foods by energy density: “green” foods can be eaten freely, “yellow” ones in moderation, and “red” foods only occasionally [2].

Physical activity

Physical activity interventions may include educational components, structured exercise programs, or both, aligned with local recommendations. The goals of exercise are to provide a safe, supportive, and enjoyable environment that encourages active play, facilitates socialization, and develops motor competence, confidence, and fundamental movement skills. Exercise programs aim to enhance physical fitness, reduce obesity-related complications, improve quality of life, and help children achieve age-appropriate activity levels. Evidence suggests that the most effective programs involve sessions of at least 60 minutes, three or more times per week, over a minimum of 12 weeks. Activities should be tailored to the child's abilities and baseline fitness, incorporating principles of frequency, intensity, duration, type, volume, and progression, while also emphasizing enjoyment and individual preferences [2].

Behavioral and psychological interventions

Behavioral interventions target diet, physical activity, sedentary behavior, and sleep. Strategies include parental engagement, home environment adjustments, screen time monitoring, and sleep hygiene improvements. Cognitive behavioral therapy is widely applied to address the cognitive and emotional factors that influence eating behaviors, self-esteem, and psychosocial wellbeing [2].



Pharmacotherapy

Currently approved pharmacological options for managing pediatric obesity include orlistat, phentermine, phentermine/topiramate, liraglutide, and semaglutide. Liraglutide and semaglutide, both GLP-1 RAs, act by enhancing satiety, delaying gastric emptying, and reducing overall food intake. Since their regulatory approval, the use of these agents in children and adolescents has increased [15].

Liraglutide has demonstrated a safety and tolerability profile in adolescents comparable to that of adults, with mostly mild adverse events and no severe complications being reported [16]. Semaglutide, administered once weekly alongside lifestyle interventions, has been associated with significant reductions in BMI and body weight, as well as improvements in cardiometabolic parameters. Adverse events are generally mild to moderate, most commonly gastrointestinal [15,16,17]. Among GLP-1 RAs, semaglutide shows superior efficacy, likely due to its molecular structure, prolonged half-life, and broader central nervous system penetration [15,17].

Surgical interventions

For adolescents with severe obesity – defined as a BMI $\geq 120\%$ of the 95th percentile – metabolic or bariatric procedures, such as Roux-en-Y gastric bypass or vertical sleeve gastrectomy, can result in substantial weight loss, with average BMI reductions of approximately 30% within the first year [18].

Pathophysiology-informed and personalized approaches

Obesity involves dysregulation of appetite, satiety, and reward pathways. Understanding these mechanisms has led to novel anti-obesity medications for monogenic/syndromic and polygenic obesity. Interventions must be sustainable, long-term, and patient-centered. Guidelines recommend early, intensive, individualized management that integrates behavioral therapy, pharmacotherapy, and, when indicated, surgery [19]. Personalized pharmacologic interventions, such as setmelanotide and metreleptin, target specific genetic defects and demonstrate clinically meaningful weight reduction under certain conditions [19].

Clinical assessment

A thorough clinical evaluation is essential to identify underlying causes, obesity-related complications, risk

of future disease, and modifiable behavioral factors. Laboratory assessments may include assays of liver function, lipid profile, fasting glucose level, glycated hemoglobin level, and oral glucose tolerance, as well as additional endocrine or genetic studies when indicated. Treatment goals include reducing adiposity, mitigating physical and psychosocial complications, and preventing chronic diseases. Interventions should be tailored to the child's preferences, family environment, and resources to include diet, exercise, behavioral therapy, and psychological support [2].

CONCLUSIONS

Childhood and adolescent obesity is a complex and multifactorial condition with significant short- and long-term health implications. Evidence suggests that prevention, early intervention, and multicomponent management strategies are most effective in achieving sustainable improvements in weight and health outcomes. Lifestyle modifications, including balanced nutrition, structured physical activity, behavioral therapy, and psychological support, remain the cornerstone of treatment. Pharmacologic interventions and bariatric surgery may be considered for selected patients with severe obesity or inadequate response to conservative approaches. Successful management relies on individualized, family-centered care, ongoing monitoring, and supportive environments that facilitate adherence to healthy behaviors. Addressing pediatric obesity requires coordinated efforts across the healthcare, community, and policy domains to reduce the global burden of this condition.

Funding statement

This study did not receive specific funding.

Acknowledgements

None.

Conflict of interest

The authors declare that they have no conflict of interest.

Use of AI tools statement

AI tools were used only for language refinement; all content and interpretations are the authors' original work.



Authors' contribution

Study design – A. Zagórska, J. Ciećwierz, M. Koczkodaj

Data collection – A. Zagórska, M. Kotowicz

Manuscript preparation – M. Zielińska, P. Szajewski, M. Bieniak

Literature research — A. Zagórska, M. Kotowicz

Final approval of the version to be published – A. Zagórska, M. Kotowicz, M. Zielińska, P. Szajewski, J. Ciećwierz, M. Koczkodaj, M. Bieniak

REFERENCES

1. Taghizadeh S, Farhangi MA. The effectiveness of pediatric obesity prevention policies: a comprehensive systematic review and dose-response meta-analysis of controlled clinical trials. *J Transl Med.* 2020;18(1):480. doi: 10.1186/s12967-020-02640-1.
2. Jebeile H, Kelly AS, O'Malley G, Baur LA. Obesity in children and adolescents: epidemiology, causes, assessment, and management. *Lancet Diabetes Endocrinol.* 2022;10(5):351–365. doi: 10.1016/S2213-8587(22)00047-X.
3. Nogueira-de-Almeida CA, Weffort VRS, Ued FDV, Ferraz IS, Contini AA, Martinez EZ, et al. What causes obesity in children and adolescents? *J Pediatr (Rio J).* 2024;100(Suppl 1):S48–S56. doi: 10.1016/j.jpeds.2023.09.011.
4. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med.* 2017;377(1):13–27. doi: 10.1056/NEJMoa1614362.
5. Stepping up action on childhood obesity. World Obesity Federation [online] <https://www.worldobesity.org/news/stepping-up-action-on-childhood-obesity> [accessed on 30 October 2025].
6. Obesity and overweight. World Health Organization, 8 December 2025 [online] <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> [accessed on 30 October 2025].
7. World Obesity Federation. Ranking (% obesity by country), children [pdf] <https://data.worldobesity.org/tables/ranking-obesity-by-country-children-4.pdf> [accessed on 30 October 2025].
8. Childhood obesity: five facts about the WHO European Region. World Health Organization, 3 March 2023 [online] <https://www.who.int/europe/news/item/03-03-2023-childhood-obesity--five-facts-about-the-who-european-region> [accessed on 30 October 2025].
9. Brief review of results from round 6 of COSI (WHO European Childhood Obesity Surveillance Initiative) 2022–2024. World Health Organization, 27 November 2024 [online] <https://www.who.int/europe/publications/brief-review-of-results-from-round-6-of-cosi-2022-2024> [accessed on 30 October 2025].
10. Dzielska A, Woynarowska M. Psychosocial predictors of body weight congruence in adolescents aged 15 and 17 years in Poland: Findings from the Health Behaviour in School-aged Children (HBSC) study. *Int J Environ Res Public Health.* 2022;19(4):2342. doi: 10.3390/ijerph19042342.
11. La Fauci G, Montalti M, Di Valerio Z, Gori D, Salomoni MG, Salussolia A, et al. Obesity and COVID-19 in Children and Adolescents: Reciprocal Detrimental Influence—Systematic Literature Review and Meta-Analysis. *Int J Environ Res Public Health.* 2022;19(13):7603. doi: 10.3390/ijerph19137603.
12. Ball GDC, Merdad R, Birken CS, Cohen TR, Goodman B, Hadjiyannakis S, et al. Managing obesity in children: a clinical practice guideline. *CMAJ* 2025;197(14):E372–E389. doi: 10.1503/cmaj.241456.
13. Fournier E, Moore H, Alghamdi ZS, Thivel D. Low-Carbohydrate Diets for the Management of Pediatric Obesity: A Systematic Review and Meta-analysis. *Nutr Rev.* 2026;84(2):267–303. doi: 10.1093/nutrit/nuaf029.
14. Lister NB, Baur LA, Felix JF, Hill AJ, Marcus C, Reinehr T, et al. Child and adolescent obesity. *Nat Rev Dis Primers.* 2023;9(1):24. doi: 10.1038/s41572-023-00435-4.
15. Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H, et al. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. *Pharmaceuticals.* 2024;17(7):828. doi: 10.3390/ph17070828.
16. Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC, et al. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12–17 Years. *J Pediatr.* 2017;181:146–153.e3. doi: 10.1016/j.jpeds.2016.10.076.
17. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-Weekly Semaglutide in Adolescents with Obesity. *N Engl J Med.* 2022;387(24):2245–2257. doi: 10.1056/NEJMoa2208601.
18. Kelly AS, Armstrong SC, Michalsky MP, Fox CK. Obesity in Adolescents: A Review. *JAMA* 2024;332(9):738–748. doi: 10.1001/jama.2024.11809.
19. Torbahn G, Lischka J, Brown T, Ells LJ, Kelly AS, Wabitsch M, et al. Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps. *Clin Endocrinol (Oxf).* 2025;102(1):51–61. doi: 10.1111/cen.15133.